News Conference News TCT 2017 FAME 2 at 3 Years: Outcomes, Symptoms Better With PCI vs OMT in Stable CAD, at Similar Cost L.A. McKeown November 02, 2017
News Conference News ESC 2017 European Societies Issue New Valvular Heart Disease Guidelines, With Important Shifts Shelley Wood August 27, 2017
News Conference News TVT 2017 Lagging Behind: Guidelines Can’t Keep Up With Growing TAVR Evidence Base Michael O'Riordan June 17, 2017
News Conference News EuroPCR 2017 TAVR Durability: Some Reassurances From CoreValve Trials Out to 9 Years Caitlin E. Cox May 17, 2017
News Conference News ACC 2017 Going to Low LDL Levels With Evolocumab Does Not Affect Memory, Brain Function: EBBINGHAUS Michael O'Riordan March 19, 2017
News Conference News ISET 2017 Forging Into the Future: Debating the Merits of TAVR in Younger, Futile, and Lower-Risk Patients Caitlin E. Cox February 06, 2017